



ASX Release

3 April 2025

Acrux receives \$1.73 million advance on FY25 R&D Tax Incentive

Melbourne, Australia; Acrux Limited (ASX:ACR), a specialty pharma company developing and commercialising a portfolio of topically applied pharmaceutical products, is pleased to announce it has received an advance of \$1.73 million from Radium Capital in relation to its FY25 R&D Tax Incentive (RDTI).

This short term funding facility gives Acrux early access to the FY25 RDTI rebate in order to support the progression of the development products and management of the Company's working capital. This advance is secured against the FY25 RDTI which is expected to be received from the Australian Taxation Office later in 2025, broadly representing 80% of the estimated rebate applicable for the eight months to 28 February 2025.

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au